The estimated Net Worth of Raymond D Jr Stapleton is at least $225 dollars as of 25 May 2022. Dr Stapleton owns over 2,500 units of Genocea Biosciences Inc stock worth over $0 and over the last 4 years he sold GNCA stock worth over $225.
Dr has made over 1 trades of the Genocea Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of GNCA stock worth $225 on 25 May 2022.
The largest trade he's ever made was selling 2,500 units of Genocea Biosciences Inc stock on 25 May 2022 worth over $225. On average, Dr trades about 625 units every 0 days since 2021. As of 25 May 2022 he still owns at least 43,750 units of Genocea Biosciences Inc stock.
You can see the complete history of Dr Stapleton stock trades at the bottom of the page.
Dr. Raymond D. Stapleton Jr. is the Exec. VP of Pharmaceutical Sciences & Manufacturing at Genocea Biosciences Inc.
Dr Jr is 50, he's been the Exec. VP of Pharmaceutical Sciences & Manufacturing of Genocea Biosciences Inc since . There are 10 older and 8 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
Raymond's mailing address filed with the SEC is C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: